The AHSG Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the AHSG gene (encoding fetuin-A) in the A-549 human non-small cell lung cancer epithelial cell line. This loss-of-function model was generated using CRISPR/Cas9-mediated gene disruption to introduce heterogeneous edits across the cell pool, resulting in a mixed population of polyclonal knockout cells. The product enables loss-of-function studies of AHSG in a cancer-relevant background without genetic bottlenecks associated with clonal selection.
The A-549 host cell line, originally derived from a 58-year-old Caucasian male with lung carcinoma, exhibits adherent epithelial morphology and is widely used as a model for lung adenocarcinoma biology. Its utility in cancer research, including studies of epithelial-mesenchymal transition, metabolic reprogramming, and cytokine signaling, provides a suitable context for investigating tumor cell-autonomous and microenvironmental roles of secreted factors such as fetuin-A.
AHSG encodes fetuin-A, a circulating glycoprotein that functions as a systemic inhibitor of insulin receptor tyrosine kinase activity and modulator of transforming growth factor-beta (TGF-beta) and bone morphogenetic protein (BMP) signaling. Fetuin-A directly binds to the insulin receptor to suppress downstream phosphorylation of IRS1 and AKT. It also interacts with TGFBR1/2 and BMP receptors to block SMAD2/3 activation, thereby inhibiting ectopic calcification. Additionally, fetuin-A acts as a negative acute-phase reactant, downregulated by pro-inflammatory cytokines such as IL-6 and TNF-alpha, while it reciprocally modulates inflammatory responses through TLR4 and NF-kB pathways. Upstream regulators including HNF1A and HNF4A control hepatic expression, and glucocorticoids and insulin further influence its levels.
In the context of A-549 cells, disruption of AHSG is expected to relieve inhibition on insulin receptor signaling, leading to enhanced insulin sensitivity and increased downstream AKT activation??a pathway intimately linked to cancer cell survival and metabolism. Loss of fetuin-A may also compromise the cell??s ability to resist TGF-beta- or BMP-induced calcification and alter cytokine secretion profiles, as A-549 cells produce and respond to various inflammatory mediators. This makes the knockout pool particularly informative for dissecting how a tumor cell line exploits fetuin-A-mediated regulatory circuits to modulate growth factor signaling and immune interactions within the lung tumor microenvironment.
Research applications of this polyclonal knockout cell product span insulin resistance studies, calcification research, and cancer metabolism investigation. The cells allow examination of fetuin-A??s impact on insulin-induced AKT phosphorylation via western blot, assessment of TGF-beta/SMAD or BMP/RUNX2 signaling perturbations by qRT-PCR and western blot, and evaluation of calcium-phosphate precipitation following BMP stimulation. Additionally, the model facilitates cytokine profiling??for example, IL-6 ELISA??to study how autocrine fetuin-A influences the inflammatory secretome in lung cancer cells. Drug screening efforts targeting kinase pathways compromised in metabolic syndrome or vascular calcification can also employ this knockout system. For further details or customized bulk orders, please contact Ascent Research.
